Όλο το DSpace

Πλοήγηση ανά Θέμα "autologous stem cell transplantation"

Αποτελέσματα 1-4 από 4

    • Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience 

      Angelopoulou M.K., Vassilakopoulos T.P., Batsis I., Sakellari I., Gkirkas K., Pappa V., Giannoulia P., Apostolidis I., Apostolopoulos C., Roussou P., Panayiotidis P., Dimou M., Kyrtsonis M.-C., Palassopoulou M., Vassilopoulos G., Moschogiannis M., Kalpadakis C., Margaritis D., Spyridonidis A., Michalis E., Anargyrou K., Repousis P., Hatzimichael E., Bousiou Z., Poulakidas E., Grentzelias D., Harhalakis N., Pangalis G.A., Anagnostopoulos A., Tsirigotis P. (2018)
      This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ...

    • Immunotherapy of systemic sclerosis 

      Katsiari C.G., Simopoulou T., Alexiou I., Sakkas L.I. (2018)
      Systemic sclerosis (SSc) is a chronic systemic disease characterized by microvasculopathy, immune activation, and extensive collagen deposition. Microvasculopathy and immune activation occur very early in the disease ...

    • Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival 

      Katodritou E., Kyrtsonis M.-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., Vasilopoulos G., Anagnostopoulos A., Kioumi A., Zikos P., Aktypi A., Briasoulis E., Megalakaki A., Repousis P., Adamopoulos I., Gogos D., Kotsopoulou M., Pappa V., Papadaki E., Fotiou D., Nikolaou E., Giannopoulou E., Hatzimichael E., Giannakoulas N., Douka V., Kokoviadou K., Timotheatou D., Terpos E. (2018)
      We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical ...

    • Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group 

      Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)
      We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...